Boson Rapid SARS-CoV-2 Antigen Home Test
COVID-19
Commercial (FDA EUA)Active
Key Facts
About LumiQuick Diagnostics
LumiQuick Diagnostics is a commercial-stage, private diagnostics company offering a diverse portfolio of rapid lateral flow tests and ELISA kits. Its product lines target human health (infectious diseases, cardiac markers, fertility, drugs of abuse), veterinary/food safety, and environmental/biothreat detection, leveraging a core immunochromatography technology platform. The company has achieved commercial traction, notably with an FDA EUA for its Boson Rapid SARS-CoV-2 Antigen Home Test, and operates in a competitive but expansive global rapid diagnostics market. Its strategy involves broadening its test menu and leveraging its QuickProfile and EnviroSafe brands across multiple sectors.
View full company profileOther COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |